Comparison of cardiovascular disease risk calculators

Current Opinion in Lipidology

Volumn 25, Issue 4, 2014, Pages 254-265

  Allan, G Michael ^a   Garrison, Scott ^a   McCormack, James ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

cardiovascular risk calculators; cardiovascular risk prediction; risk estimation models

Indexed keywords

AREA UNDER THE CURVE; ASSIGN SCORE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CARDIOVASCULAR RISK CALCULATOR; COMPARATIVE STUDY; CORONARY ARTERY CALCIUM SCORE; CUORE MODEL; FRAMINGHAM RISK SCORE; HUMAN; MATHEMATICAL MODEL; MEDICAL DECISION MAKING; META ANALYSIS (TOPIC); NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PREDICTION; PRIMARY PREVENTION; PRIORITY JOURNAL; PROCAM SCORE; QRISK SCORE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SCORE MODEL; UKPDS RISK ENGINE;

EID: 84904195857     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000095     Document Type: Review

References (44)

1. Scruth E, Worrall-Carter L, Cheng E, et al. Assessing risk post intervention for an acute coronary syndrome: A review of the risk assessment tools and their development. Contemp Nurse 2012; 43:2-12.
2. Grover SA, Lowensteyn I, Esrey KL, et al. Do doctors accurately assess coronary risk in their patients? Preliminary results of the Coronary Health Assessment Study. BMJ 1995; 310:975-978.
3. Sposito AC, Ramires JA, Jukema JW, et al. Physicians' attitudes and adherence to use of risk scores for primary prevention of cardiovascular disease: Cross-sectional survey in three world regions. Curr Med Res Opin 2009; 25:1171-1178.
4. McManus RJ, Mant J, Meulendijks CF, et al. Comparison of estimates and calculations of risk of coronary heart disease by doctors and nurses using different calculation tools in general practice: Cross sectional study. BMJ 2002; 324:459-464.
5. van der Weijden T, van Steenkiste B, Stoffers HE, et al. Primary prevention of cardiovascular diseases in general practice: Mismatch between cardiovascular risk and patients' risk perceptions. Med Decis Making 2007; 27:754-761.
6. Brekke M, Straand J. Does present use of cardiovascular medication reflect elevated cardiovascular risk scores estimated ten years ago? A population based longitudinal observational study. BMC Public Health 2011; 11:144.
7. Joffres M, Shields M, Tremblay MS, Gorber SC. Dyslipidemia prevalence, treatment, control, and awareness in the Canadian Health Measures Survey. Can J Public Health 2013; 104:e252-e257.
8. Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: Meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380:581-590.
9. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol 2013. [Epub ahead of print]. doi: 10.1016/j.jacc.2013.11.002.
10. Wierzbicki A, Ahmad R, Banks L, et al. Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. NICE 2014; http://www.nice.org.uk/nicemedia/live/13637/ 66547/66547.pdf [Accessed Feb 16, 2014]
11. Matheny M, McPheeters ML, Glasser A, et al. Systematic review of cardiovascular disease risk assessment tools [Internet]. Agency for Healthcare Research and Quality (US); 2011 May. Report No.: 11-05155-EF-1. https://www. ncbi.nlm.nih.gov/books/NBK56166/pdf/TOC.pdf (Accessed Feb 18, 2014).
12. van Dieren S, Beulens JW, Kengne AP, et al. Prediction models for the risk of cardiovascular disease in patients with type 2 diabetes: A systematic review. Heart 2012; 98:360-369.
13. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991; 121:293-298.
14. Reynolds TM, Twomey P, Wierzbicki AS. Accuracy of cardiovascular risk estimation for primary prevention in patients without diabetes. J Cardiovasc Risk 2002; 9:183-190.
15. Siontis GC, Tzoulaki I, Siontis KC, Ioannidis JP. Comparisons of established risk prediction models for cardiovascular disease: Systematic review. BMJ 2012; 344:e3318.
16. Brindle P, Emberson J, Lampe F, et al. Predictive accuracy of the Framingham coronary risk score in British men: Prospective cohort study. BMJ 2003; 327:1267.
17. Marrugat J, D'Agostino R, Sullivan L, et al. An adaptation of the Framingham coronary heart disease risk function to European Mediterranean areas. J Epidemiol Community Health 2003; 57:634-638.
18. Liu J, Hong Y, D'Agostino RB Sr, et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA 2004; 291:2591-2599.
19. Asia Pacific Cohort Studies Collaboration, Barzi F, Patel A, Gu D, et al. Cardiovascular risk prediction tools for populations in Asia. J Epidemiol Community Health 2007; 61:115-121.
20. Allan GM, Nouri F, Korownyk C, et al. Agreement among cardiovascular risk calculators. Circulation 2013; 127:1948-1956.
21. Framingham Heart Study. History of the Framingham Heart Study. 2014. http://www.framinghamheartstudy.org/about-fhs/history.php (Accessed Feb 17, 2014).
22. Collins GS, Altman DG. Predicting the 10 year risk of cardiovascular disease in the United Kingdom: Independent and external validation of an updated version of QRISK2. BMJ 2012; 344:e4181.
23. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: The SCORE project. Eur Heart J 2003; 24:987-1003.
24. Pocock SJ, McCormack V, Gueyffier F, et al. A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials. BMJ 2001; 323:75-81.
25. Stevens RJ, Kothari V, Adler AI, et al. The UKPDS risk engine: A model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond) 2001; 101:671-679.
26. D'Agostino RB Sr, Grundy S, Sullivan LM, et al. Validation of the Framingham coronary heart disease prediction scores: Results of a multiple ethnic groups investigation. JAMA 2001; 286:180-187.
27. Sheridan S, Pignone M, Mulrow C. Framingham-based tools to calculate the global risk of coronary heart disease: A systematic review of tools for clinicians. J Gen Intern Med 2003; 18:1039-1052.
28. Saidj M, Jørgensen T, Prescott E, Borglykke A. Poor predictive ability of the risk chart SCORE in a Danish population. Dan Med J 2013; 60:A4609.
29. Soureti A, Hurling R, Murray P, et al. Evaluation of a cardiovascular disease risk assessment tool for the promotion of healthier lifestyles. Eur J Cardiovasc Prev Rehabil 2010; 17:519-523.
30. Lopez-Gonzalez AA, Aguilo A, Frontera M, et al. Effectiveness of the Heart Age tool for improving modifiable cardiovascular risk factors in a Southern European population: A randomized trial. Eur J Prev Cardiol 2014; Feb 3.
31. National Cholesterol Education Program (NCEP) Expert Panel. Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). National Heart, Lung, and Blood Institute, National Institute of Health 2002; pp. 1-284. http://www.nhlbi.nih.gov/guidelines/cholesterol/ atp3full.pdf [Accessed Feb 20, 2014].
32. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21:1011-1053.
33. Ridker PM, Cook NR. Statins: New American guidelines for prevention of cardiovascular disease. Lancet 2013; 382:1762-1765.
34. Ioannidis JP. More than a billion people taking statins? Potential implications of the new cardiovascular guidelines. JAMA 2014; 311:463-464.
35. Trewby PN, Reddy AV, Trewby CS, et al. Are preventive drugs preventive enough? A study of patients' expectation of benefit from preventive drugs. Clin Med 2002; 2:527-533.
36. Gaziano TA, Young CR, Fitzmaurice G, et al. Laboratory-based versus nonlaboratory-based method for assessment of cardiovascular disease risk: The NHANES I Follow-up Study cohort. Lancet 2008; 371:923-931.
37. Tzoulaki I, Liberopoulos G, Ioannidis JP. Assessment of claims of improved prediction beyond the Framingham risk score. JAMA 2009; 302:2345-2352.
38. Tzoulaki I, Siontis KC, Evangelou E, Ioannidis JP. Bias in associations of emerging biomarkers with cardiovascular disease. JAMA Intern Med 2013; 173:664-671.
39. Yeboah J, McClelland RL, Polonsky TS, et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediaterisk individuals. JAMA 2012; 308:788-795.
40. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006; 355:2631-2639.
41. McCormack J, Allan GM. Measuring hsCRP-an important part of a comprehensive risk profile or a clinically redundant practice? PLoS Med 2010; 7:e1000196.
42. Den Ruijter HM, Peters SA, Anderson TJ, et al. Common carotid intima-media thickness measurements in cardiovascular risk prediction: A meta-analysis. JAMA 2012; 308:796-803.
43. Helfand M, Buckley DI, Freeman M, et al. Emerging risk factors for coronary heart disease: A summary of systematic reviews conducted for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 151: 496-507.
44. Gaziano JM, Wilson PW. Cardiovascular risk assessment in the 21st century. JAMA 2012; 308:816-817.